Research graph
References from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
10.1056/evidoa2200015 · 2022 · External reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · 2023 · External reference
Precision medicine in biliary tract cancer
10.1200/jco.21.02576 · 2022 · External reference
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
10.1093/annonc/mdy263 · 2018 · External reference
ESMO Scale for Clinical Actionability of molecular Targets driving targeted treatment in patients with cholangiocarcinoma
10.1158/1078-0432.ccr-21-2384 · 2022 · External reference
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
10.1016/j.annonc.2024.04.005 · 2024 · External reference
ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer
10.1016/j.esmoop.2024.104003 · 2025 · External reference
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
10.1016/j.annonc.2022.05.520 · 2022 · External reference
Application of cell-free DNA analysis to cancer treatment
10.1056/nejmra1706174 · 2018 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer
10.1002/1878-0261.12547 · 2019 · External reference
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma [Internet]
2021 · External reference
FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion [Internet]
2020 · External reference
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
10.1016/j.annonc.2020.07.014 · 2020 · External reference
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
10.1016/j.jhep.2024.10.020 · 2025 · External reference
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
10.1016/j.annonc.2022.09.150 · 2022 · External reference
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
10.1016/s1470-2045(20)30109-1 · 2020 · External reference
Futibatinib for FGFR2 -rearranged intrahepatic cholangiocarcinoma
10.1056/nejmoa2206834 · 2023 · External reference
Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation
10.1158/1078-0432.ccr-23-3321 · 2024 · External reference
